CBDCA: phase II evaluation in advanced colorectal carcinoma

Area of Science:

• Oncology
• Pharmacology

Background:

• Colorectal carcinoma is a significant global health concern.
• Chemotherapy remains a cornerstone in managing advanced colorectal cancer.

Purpose of the Study:

• To evaluate the efficacy and toxicity of Carboplatin (CBDCA) in patients with measurable colorectal carcinomas.
• To determine the optimal dosing schedule for CBDCA in this patient population.

Main Methods:

• A cohort of 25 patients with measurable colorectal carcinomas received Carboplatin (CBDCA).
• Dosing started at 400 mg/m2 every 28 days, with potential escalation to 450 mg/m2.
• Toxicity and response assessments were performed on all patients.

Main Results:

• No complete responses were observed in the patient cohort.
• One partial response, lasting 23 weeks, was documented.
• The primary toxicity observed was hematological; no auditory or renal toxicities were reported.

Conclusions:

• Carboplatin (CBDCA), at the tested dosage and schedule, demonstrated limited therapeutic efficacy in previously untreated colorectal carcinoma patients.
• The observed toxicity profile was primarily hematological, with a notable absence of auditory or renal adverse effects.